Jul. 16 at 8:37 PM
$OTLK Funny how everyone assumes “authorized shares” automatically means disaster.
I remember exactly the same panic with
$KOD. Everyone expected immediate dilution at depressed prices. Instead, the company later raised capital at a premium valuation after the story improved. Yes, shareholders were diluted, but the stock continued to perform well because the financing created value.
Could Outlook do the same? Nobody knows. But if FDA approval comes, I’d much rather see a financing at a premium price to accelerate commercialization than a desperate raise at
$1.50.
And yes… both companies happen to be in ophthalmology. 😉
